TrialInternational journal of hematology2014

Phase III, single-arm study investigating the efficacy, safety, and tolerability of anagrelide as a second-line treatment in high-risk Japanese patients with essential thrombocythemia.

Yuzuru Kanakura et al.PubMed ↗Publisher ↗

No numbers read from the abstract.